Intended Audience:
The program is intended for oncologists, hematologists, coagulation experts, internists, nurse practitioners, and related disciplines

Registration:
Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:
Supported by an independent educational grant from Eisai, Inc.

Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials


Faculty Disclosures:

Craig M. Kessler, MD
Grants/research support: sanofi-aventis, Eisai, GlaxoSmithKline, Octapharma
Consultant: sanofi-aventis, Eisai, NovoNordisk

Frederick Rickles, MD
Consultant for Pfizer, Eisai, sanofi-aventis,
and Bristol-Myers Squibb
Speakers Bureau: Eisai

John Fanikos, RPh, MBA
Speakers Bureau and Consulting: Abbott Laboratories, Astra-Zeneca, Eisai Pharmaceuticals, Genentech, GlaxoSmithKline, sanofi-aventis, The Medicines Company



Program Faculty:
Craig M. Kessler, MD
Professor of Medicine and Pathology
Georgetown University Medical Center
Director of the Division of Coagulation
Department of Laboratory Medicine
Washington, DC

Frederick Rickles, MD
Professor of Medicine, Pediatrics, Pharmacology and Physiology
Department of Medicine
Division of Hematology-Oncology
The George Washington University
Washington, DC

John Fanikos, RPh, MBA
Assistant Director of Pharmacy
Brigham and Women’s Hospital
Assistant Clinical Professor of Pharmacy
Northeastern University
Massachusetts College of Pharmacy
Boston, MA

Educational Objectives:

•Clinicians will review recent trials, research, and expert analysis of issues focused on thrombosis and cancer.

•Clinicians will specify strategies for risk-directed prophylaxis against DVT in at risk patients with cancer.

•Clinicians will explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT.

•Clinicians will describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis.

•Clinicians will review landmark clinical trials focusing on DVT prophylaxis in patients with cancer.

•Clinicians will explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy